Pliant's Lead Drug Shows Promising Results in Chronic Liver Disease Study
TL;DR Summary
Pliant Therapeutics has reported positive early-stage results from an exploratory study, indicating that patients with chronic liver disease who received its drug, bexotegrast, showed improved liver function compared to those who received a placebo. The study showed reduced levels of liver scarring biomarkers in patients who received the drug.
Topics:business#biomarkers#chronic-liver-disease#drug-study#health#liver-function#pliant-therapeutics
- Pliant shares spike on exploratory study results of lead drug in chronic liver disease Endpoints News
- Pliant bends investors to its will, sending stock up with early evidence of efficacy in liver disease FierceBiotech
- Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis GlobeNewswire
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
61%
127 → 49 words
Want the full story? Read the original article
Read on Endpoints News